HIV and AIDS Trial, Recruiting (NCT06730555)

HIV and AIDS Trial, Recruiting NCT06730555 Sponsor: University of Miami Condition: HIV and AIDS

Printed from Voxsanity (voxsanity.com.au) — NCT06730555 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hiv Aids

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The trial site must be a syringe services program (SSP) — a program that provides clean needles and related support — located in an area identified by the CDC or the Ending the HIV Epidemic initiative as a high-priority or vulnerable location for HIV
The SSP must serve at least 300 different people per year
The SSP must not currently offer HIV/HCV (Hepatitis C) testing in an "opt-out" format (where testing is offered automatically unless someone declines)
The SSP must be able and willing to collect and share grouped, site-level data on how many people are offered HIV/HCV screening, how many complete testing, and how many are connected to care, along with general participant information
Key staff at the SSP must be willing to take part in surveys, interviews, and coaching sessions throughout the study

Who may not be able to join:

SSPs that currently receive, or have previously received, funding from the FOCUS (Frontline Communities in the United States) program
SSPs that have already introduced opt-out HIV/HCV testing
SSPs that are currently taking part in another related study called SAIA-SSP-HIV (clinical trial NCT06025435)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tyler Bartholomew, PhD, University of Miami

Phone: 3056897030

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06730555

Sponsor: University of Miami

Phase: Not Applicable

Status: Recruiting

Condition: HIV and AIDS

Trial contact: 3056897030

More information: https://clinicaltrials.gov/study/NCT06730555

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The trial site must be a syringe services program (SSP) — a program that provides clean needles and related support — located in an area identified by the CDC or the Ending the HIV Epidemic initiative as a high-priority or vulnerable location for HIV
The SSP must serve at least 300 different people per year
The SSP must not currently offer HIV/HCV (Hepatitis C) testing in an "opt-out" format (where testing is offered automatically unless someone declines)
The SSP must be able and willing to collect and share grouped, site-level data on how many people are offered HIV/HCV screening, how many complete testing, and how many are connected to care, along with general participant information
Key staff at the SSP must be willing to take part in surveys, interviews, and coaching sessions throughout the study

Who may not be able to join:

SSPs that currently receive, or have previously received, funding from the FOCUS (Frontline Communities in the United States) program
SSPs that have already introduced opt-out HIV/HCV testing
SSPs that are currently taking part in another related study called SAIA-SSP-HIV (clinical trial NCT06025435)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Miami

Registry

ClinicalTrials.gov

Start date

27 June 2025

Est. completion

1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of SSP participants reached; Adoption

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov